Literature DB >> 29319497

Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii.

Youfa Qin, Jie Zhang, Lei Wu, Dailong Zhang, Lunjiao Fu, Xiaoyan Xue.   

Abstract

OBJECTIVE: The present study examined the effect of high-dose cefoperazone-sulbactam combined with tigecycline against ventilator-associated pneumonia (VAP) caused by extensively drug-resistant Acinetobacter baumannii(XDR-AB).
MATERIALS AND METHODS: 42 patients with VAP due to XDR-AB infection were randomized into two groups: the TIG group (received tigecycline injection) and the TIG+CFS group (received tigecycline and cefoperazone-sulbactam (1 : 1) injection). Pulsed field gel electrophoresis (PFGE) was used for genotyping the isolated XDR-AB. The microdilution method was used to test the minimum inhibitory concentration (MIC) of cefoperazone-sulbactam or tigecycline in vitro and the combined effect was determined with the checkerboard method.
RESULTS: The total combined effectiveness rate (including all patients who demonstrated an improved condition) was significantly higher in the TIG+CFS group (85.7%) compared with the TIG group (47.6%) (p = 0.010). No significant differences were noted with regard to the adverse reactions between the two groups. The 42 isolated XDR-AB strains were classified into four types. The MIC of the two drugs in combination was significantly lower than that of each drug used alone (p < 0.05).
CONCLUSION: High dose of cefoperazone-sulbactam can improve the antimicrobial activity of tigecycline against XDR-AB.
.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29319497     DOI: 10.5414/CP203102

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  6 in total

1.  Extensive drug resistant Acinetobacter baumannii: a comparative study between non-colistin based combinations.

Authors:  Eman Elsayed; Mohamed A Elarabi; Dana A Sherif; Mohamed Elmorshedi; Noha El-Mashad
Journal:  Int J Clin Pharm       Date:  2019-11-19

Review 2.  Leveraging laboratory and clinical studies to design effective antibiotic combination therapy.

Authors:  Kathleen Davis; Talia Greenstein; Roberto Viau Colindres; Bree B Aldridge
Journal:  Curr Opin Microbiol       Date:  2021-10-08       Impact factor: 7.934

3.  Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.

Authors:  Sarah Melissa Nørgaard; Camilla Skaarup Jensen; Josefine Aalestrup; Christina M J E Vandenbroucke-Grauls; Mark G J de Boer; Alma Becic Pedersen
Journal:  Antimicrob Resist Infect Control       Date:  2019-11-04       Impact factor: 4.887

4.  Effects of Tigecycline combined with Cefoperazone on bacterial clearance and serum biochemical indexes in patients with pulmonary infections in ICU.

Authors:  Nina Li; Huiyan Zhang
Journal:  Pak J Med Sci       Date:  2022 Jul-Aug       Impact factor: 2.340

5.  A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections.

Authors:  Qingyi Shi; Chen Huang; Tingting Xiao; Zhenzhu Wu; Yonghong Xiao
Journal:  Antimicrob Resist Infect Control       Date:  2019-04-25       Impact factor: 4.887

6.  High-Dose Tigecycline in Elderly Patients with Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii in Intensive Care Unit.

Authors:  Xiang-Rong Bai; De-Chun Jiang; Su-Ying Yan
Journal:  Infect Drug Resist       Date:  2020-05-18       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.